Previous 10 | Next 10 |
Buying Penny Stocks Today? Here’s What You Need to Know With another potentially volatile day of trading for penny stocks and blue chips, there is a lot for investors to consider. As we all know, the largest contributing factor to stock market movement right now is the war going ...
GoodRx has agreed to acquire vitaCare for $150 million in cash, with an additional $7 million consideration contingent upon vitaCare’s financial performance through 2023 TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an inno...
-Executive Management to Host Conference Call on March 10, 2022, at 8:30 a.m. ET- TherapeuticsMD, Inc. (“TXMD” or the “Company”) (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that it will report its fourth q...
Shares of leading healthcare company TherapeuticsMD (TXMD) declined by 72.9% in price last year as the company suffered losses and negative cash flows. In addition, given worries surrounding the stock's non-compliance with Nasdaq's listing rules, is it wise to bet on the stock now? Read on, l...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, trader! Let’s start off the day right with a look into the biggest pre-market stock movers for Thursday! Source: ventdusud / Shutterstock.com Loads of penny stocks are on the move today and we...
TherapeuticsMD (NASDAQ:TXMD) announced that the FDA had not approved the revisions sought by the company to certain manufacturing specifications related to ANNOVERA, a ring-shaped contraceptive marketed by the company for women. In a Supplemental New Drug Application ((sNDA)), TherapeuticsMD ...
- FDA determined that it could not approve proposed revisions to the manufacturing testing limits requested through the Supplemental New Drug Application (sNDA) - - FDA provided recommendations and requested additional information to address the issues - - The Company will continue ...
TherapeuticsMD (NASDAQ:TXMD) announces the settlement of the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals (NYSE:AMRX). TXMD shares up 2% premarket at $0.45. As part of the settlement, TXMD granted to Amneal a license to commercialize latter's ge...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the settlement of the previously disclosed U.S. patent litigation for BIJUVA® with Amneal Pharmaceuticals, Inc., Amneal Pharmaceuticals, LLC, and Amneal Pharmaceuticals of...
During the semi-annual review, Clovis Oncology (CLVS -1.1%), 22nd Century Group (XXII -1.2%), Verastem (VSTM +8.7%), Omeros (OMER -0.7%), Therapeutics MD (TXMD -3.2%), CEL-SCI (CVM +2.1%), ZIOPHARM Oncology (ZIOP -1.9%), Karyopharm Therapeutics (KPTI +1.1%), Esperion Therapeutics (E...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...